Multi-modal biomarker profiling spanning neurodegeneration, immunology, cardiac biology, and oncology — integrating Western blot, flow cytometry, immunofluorescence, ELISA/Luminex, and mass spectrometry–based proteomics for translational drug discovery.
Comprehensive biomarker quantification across multiple analytical platforms, enabling precise characterization of disease mechanisms and therapeutic response. Integration of complementary technologies provides multi-dimensional insights into cellular and molecular pathology.
Comprehensive profiling of α-synuclein pathology, lysosomal dysfunction, autophagy impairment, and dopaminergic neuronal viability in Parkinson's disease models.
Confocal imaging of cytokine receptor expression in iPSC-derived neurons co-cultured with activated microglia and PFF488. Multichannel panels show receptor signal (top), Hoechst nuclear stain, Tuj1 neuronal marker, composite overlay, and magnified insets with arrowheads marking PFF aggregates at neuronal processes.
Time-resolved phospho-synuclein (pSyn) inclusion growth in TH+ dopaminergic neurons exposed to PFF + IFN-γ over 7, 10, and 14 days. Deconvoluted images with measurements (µm) show progressive inclusion maturation and coalescence, providing quantitative morphometric data for biomarker tracking.
Confocal time course of α-synuclein-HA expressing neurons probed with two independent phospho-synuclein antibodies (phospho S129 and pSyn#64). Control neurons show diffuse cytoplasmic α-syn-HA signal, while IFN-γ–treated neurons develop perinuclear pS129-positive inclusions by day 7, progressively maturing through day 14 — validating the biomarker with orthogonal antibody approaches.
Multi-target Western blot panel across three cell lines (U2OS, U87, SH-SY5Y) under control, IFN-γ, PFF, and PFF+IFN conditions. Biomarkers quantified include CHC (clathrin heavy chain), LAMP1, LAMP2, NRF2, TFEB, and α-synuclein — capturing endocytic machinery, lysosomal integrity, oxidative stress response, and protein aggregation state in a single pharmacodynamic readout.
Comprehensive immunophenotyping of T cell activation, checkpoint receptor expression, cytokine secretion, and immune cell subset composition for cancer immunotherapy assessment.
Quantitative evaluation of cardiomyocyte-specific proteins, structural integrity, and cell purity for pluripotent stem cell-derived and primary cardiomyocyte characterization.
Comprehensive proteome-wide and transcriptome-wide biomarker discovery using mass spectrometry and next-generation sequencing technologies, enabling unbiased identification of disease-relevant molecular signatures.
